Depression and immunity: Biological and behavioural mechanisms

Depression and Physical Illness

Volumn , Issue , 2006, Pages 299-320

  Irwin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548022946     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544293.015     Document Type: Chapter

References (131)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn (Washington, DC: American Psychiatric Association, 2000).
2. M. H. Rapaport, L. L. Judd, P. J. Schettler, et al., A descriptive analysis of minor depression. Am. J. Psychiatry 159 (2002), 637–43.
3. A. K. Berger, B. J. Small, Y. Forsell, L. Backman, Preclinical symptoms of major depression in very old age: a prospective longitudinal study. Am. J. Psychiatry 155 (1998), 1039–43.
4. J. M. Lyness, E. D. Caine, Y. Conwell, D. King, Depressive symptoms, medical illness, and functional status in depressed psychiatric inpatients. Am. J. Psychiatry 150 (1993), 910–15.
5. R. D. Hays, K. B. Wells, C. D. Sherbourne, W. Rogers, K. Spritzer, Functioning andwell-being outcomes of patientswith depression comparedwith chronic general medical illnesses. Arch. Gen. Psychiatry 52 (1995), 11–19.
6. L. R. Wulsin, G. E. Vailant, V. E. Wells, A systematic review of the mortality of depression. Psychosom. Med. 61 (1999), 6–17.
7. M. L. Bruce, P. J. Leaf, G. P. Rozal, L. Florio, R. A. Hoff, Psychiatric status and 9-year mortality data in the New Haven Epidemiologic Catchment Area Study. Am. J. Psychiatry 151 (1994), 716–21.
8. C. Herrmann, S. Brand-Driehorst, B. Kaminsky, et al., Diagnostic groups and depressed moodas predictors of 22-monthmortality in medical inpatients. Psychosom.Med. 60 (1998), 570–77.
9. B. W. Rovner, Depression and increased risk of mortality in the nursing home patient. Am. J. Med. 94 (1993), 19–22S.
10. N. Frasure-Smith, F. Lespérance, M. Talajic, Depression following myocardial infarction: impact on 6-month survival. J. Am. Med. Assoc. 270 (1993), 1819–25.
11. N. Frasure-Smith, F. Lespérance, M. Talajic, The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol. 14 (1995), 388–98.
12. M. A. Dew, C. C. Hoch, D. J. Buysse, et al., Healthy older adults’ sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom. Med. 65 (2003), 63–73.
13. D. F. Kripke, L. Garfinkel, D. L. Wingard, M. R. Klauber, M. R. Marler, Mortality associated with sleep duration and insomnia. Arch. Gen. Psychiatry 59 (2002), 131–6.
14. D. Gottlieb, D. Schulman, B. Nam, R. Agostino, W. Kannel, Sleepdurationpredictsmortality: the Framingham study. Presented at the 16th AnnualMeeting of the Associated Professional Sleep Societies, 8–13 June 2002, Seattle, WA.
15. A. B. Newman, C. F. Spiekerman, P. Enright, et al., Daytime sleepiness predicts mortality and cardiovascular disease in older adults: the Cardiovascular Health Study Research Group. J. Am. Geriatr. Soc. 48 (2000), 115–23.
16. M. J. Owens, C. B. Nemeroff, Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 91 (1991), 425–73.
17. E. M. Friedman, M. A. Irwin, A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Ann. N. Y. Acad. Sci. 771 (1995), 396–418.
18. E. M. Friedman, M. R. Irwin, Modulationofimmune cell function by the autonomic nervous system. Pharmacol. Ther. 74 (1997), 27–38.
19. M. Irwin, W. Vale, C. Rivier, Central corticotropin-releasing factor mediates the suppressive effect of stress on natural killer cytotoxicity. Endocrinology 126 (1990), 2837–44.
20. M. Irwin, Brain corticotropin releasing hormone- and interleukin-1β-induced suppression of specific antibody production. Endocrinology 133 (1993), 1352–60.
21. M. Irwin, M. Brown, T. Patterson, et al., Y. Neuropeptide and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J. 5 (1991), 3100–107.
22. V. M. Sanders, R. H. Straub, Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav. Immun. 16 (2002), 290–332.
23. J. A. Moynihan, S. Y. Stevens, Mechanisms of stress-induced modulation of immunity in animals. In Psychoneuroimmunology, ed. R. Ader, D. L. Felten, N. Cohen (San Diego, CA: Academic Press, 2001), pp. 227–50.
24. F. S. Dhabhar, A. H. Miller, B. S. McEwen, R. L. Spencer, Stress-induced changes in blood leukocyte distribution: role of adrenal steroid hormones. J. Immunol. 157 (1996), 1638–44.
25. M. Irwin, T. Patterson, T. L. Smith, et al., Reduction of immune function in life stress and depression. Biol. Psychiatry 27 (1990), 22–30.
26. M. Irwin, H. Weiner, Depressive symptoms and immune function during bereavement. In Biopsychosocial Aspects of Bereavement, ed. S. Zisook (Washington, DC: APA Press, 1987), pp. 156–74.
27. M. Maes, M. Van der Planken, W. J. Stevens, et al., Leukocytosis, monocytosis, and neutrophilia: hallmarks of severe depression. J. Psychiatr. Res. 26 (1992), 125–34.
28. Z. Kronfol, R. Turner, H. Nasrallah, G. Winokur, Leukocyte regulation in depression and schizophrenia. Psychiatry Res. 13 (1984), 13–18.
29. M. Irwin, T. L. Smith, J. C. Gillin, Low natural killer cytotoxicity in major depression. Life Sci. 41 (1987), 2127–33.
30. P. Surtees, N. Wainwright, N. Day, et al., Association of depressionwith peripheral leukocyte counts in EPIC-Norfolk-role of sex and cigarette smoking. J. Psychsom. Res. 54 (2003), 303–6.
31. S. J. Schleifer, J. A. Bartlett, S. E. Keller, et al., Immunity in adolescentswith major depression. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002), 1054–60.
32. T. B. Herbert, S. Cohen, Depression and immunity: a meta-analytic review. Psychol. Bull. 113 (1993), 472–86.
33. D. L. Evans, J. D. Folds, J. M. Petitto, et al., Circulating natural killer cell phenotypes in men and women with major depression. Arch. Gen. Psychiatry 49 (1992), 388–95.
34. S. J. Schleifer, S. E. Keller, R. N. Bond, J. Cohen, M. Stein, Major depressive disorder and immunity: role of age, sex, severity, and hospitalization. Arch. Gen. Psychiatry 46 (1989), 81–7.
35. E. P. Zorrilla, L. Luborsky, J. R. McKay, et al., The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15 (2001), 199–226.
36. Z. Kronfol, J. D. House, Depression, hypothalamic-pituitary adrenocortical activity and lymphocyte function. Psychopharmacol. Bull. 21 (1985), 476–8.
37. Z. Kronfol, J. Silva, J. Greden, et al., Impaired lymphocyte function in depressive illness. Life Sci. 33 (1983), 241–7.
38. J. Albrecht, J. Helderman, M. Schlesser, J. Rush, A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Res. 15 (1985), 185–93.
39. E. Syvalahti, J. Eskola, O. Ruuskanen, T. Laine, Nonsuppression of cortisol and immune function in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 9 (1985), 413–22.
40. S. J. Schleifer, S. E. Keller, S. G. Siris, K. L. Davis, M. Stein, Depression and immunity: lymphocyte function in ambulatory depressed patients, hospitalized schizophrenic patients, and patients hospitalized for herniorrhaphy. Arch. Gen. Psychiatry 42 (1985), 129–33.
41. Z. Kronfol, J. D. House, J. Silva, J. Greden, B. J. Carroll, Depression, urinary free cortisol excretion, and lymphocyte function. Br. J. Psychiatry 148 (1986), 70–73.
42. J. R. Calabrese, R. G. Skwerer, B. Barna, et al., Depression, immunocompetence, and prostaglandins of the E-series. Psychol. Res. 17 (1986), 41–7.
43. M. T. Lowy, A. T. Reder, G. J. Gormley, H. Y. Meltzer, Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol. Psychiatry 24 (1988), 619–30.
44. M. Maes, E. Bosmans, E. Suy, B. Minner, J. Raus, Impaired lymphocyte stimulation by mitogens in severely depressed patients: a complex interface with HPA axis hyperfunction, noradrenergic activity and the ageing process. Br. J. Psychiatry 155 (1989), 793–8.
45. L. L. Altshuler, S. Plaeger-Marshall, S. Richeimer, M. Daniels, L. R. Baxter, Jr, Lymphocyte function in major depression. Acta Psychiatr. Scand. 80 (1989), 132–6.
46. D. F. Darko, J. C. Gillin, S. C. Risch, et al., Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression. Biol. Psychiatry 26 (1989), 145–55.
47. Z. Kronfol, M. Nair, J. Goodson, et al., Natural killer cell activity in depressive illness: a preliminary report. Biol. Psychiatry 26 (1989), 753–6.
48. P. Cosyns, M. Maes, M. Vandewoude, et al., Impaired mitogen-induced lymphocyte responses and the hypothalamic-pituitary-adrenal axis in depressive disorders. J. Affect. Disord. 16 (1989), 41–8.
49. C. Bartoloni, L. Guidi, L. Antico, et al., Psychological status of institutionalized aged: influences on immune parameters and endocrinological correlates. Int. J. Neurosci. 51 (1990), 279–81.
50. C. McAdams, B. E. Leonard, Neutrophil and monocyte phagocytosis in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 17 (1993), 971–84.
51. B. Birmaher, B. S. Rabin, M. R. Garcia, et al., Cellular immunity in depressed, conduct disorder, and normal adolescents: role of adverse life events. J. Am. Acad. Child Adolesc. Psychol. 33 (1994), 671–8.
52. S. J. Schleifer, S. E. Keller, J. A. Bartlett, Panic disorder and immunity: few effects on circulating lymphocytes, mitogen response, and NK cell activity. Brain Behav. Immun. 16 (2002), 698–705.
53. M. Stein, A. H. Miller, R. L. Trestman, Depression, the immune system, and health and illness. Arch. Gen. Psychiatry 48 (1991), 171–7.
54. M. Irwin, C. Miller, Decreased natural killer cell responses and altered interleukin-6 and interleukin-10 production in alcoholism: an interaction between alcohol dependence and African-American ethnicity. Alcohol Clin. Exp. Res. 24 (2000), 560–69.
55. M. Irwin, Effects of sleep and sleep loss on immunity and cytokines. Brain Behav. Immun. 16 (2002), 503–12.
56. P. C. Mohl, L. Huang, C. Bowden, et al., Natural killer cell activity in major depression. Am. J. Psychiatry 144 (1987), 1619.
57. Z. Kronfol, D. G. Remick, Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 157 (2000), 683–94.
58. M. E. Bauer, A. Papadopoulos, L. Poon, et al., Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 28 (2003), 49–65.
59. A. Seidel, V. Arolt, M. Hunstiger, et al., Cytokine production and serum proteins in depression. Scand. J. Immunol. 41 (1995), 534–8.
60. PTrzonkowski, J. Mysliwska, B. Godlewska, et al., Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav. Immun. 18 (2004), 135–48.
61. M. A. Maes, review on the acute phase response in major depression. Rev.Neurosci. 4 (1993), 407–16.
62. M. Maes, S. Scharpe, L. Van Grootel, et al., Higher alpha 1-antritrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory respose during that illness. J. Affect. Disord. 24 (1992), 183–92.
63. D. L. Musselman, A. H. Miller, M. R. Porter, et al., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158 (2001), 1252–7.
64. G. E. Miller, C. A. Stetler, R. M. Carney, K. E. Freedland, W. A. Banks, Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 90 (2002), 1279–83.
65. J. L. Pike, M. R. Irwin, Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 20 (2006), 169–74.
66. B. W. Penninx, S. B. Kritchevsky, K. Yaffe, et al., Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 54 (2003), 566–72.
67. F. Brambilla, P. Monteleone, M. Maj, Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J. Affect. Disord. 78 (2004), 273–7.
68. J. Stastny, A. Konstantinidis, M. J. Schwarz, et al., Effects of tryptophan depletion and catecholamine depletion on immune parameters in patientswith seasonal affective disorder in remission with light therapy. Biol. Psychiatry 53 (2003), 332–7.
69. F. Lesperance, N. Frasure-Smith, P. Theroux, M. Irwin, The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and Creactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry 161 (2004), 271–7.
70. A. J. Zautra, D. C. Yocum, I. Villanueva, et al., Immune activation and depression in women with rheumatoid arthritis. J. Rheumatol. 31 (2004) 457–63.
71. A. H. Miller, Cytokines and sickness behavior: implications for cancer care and control. Brain Behav. Immun. 17: Suppl 1 (2003), 132–4.
72. G. E. Miller, S. Cohen, S. Pressman, et al., Psychological stress and antibody response to influenza vaccination: when is the critical period for stress, and how does it get inside the body? Psychosom. Med. 66 (2004), 215–23.
73. M. Irwin, C. Costlow, H. Williams, et al., Cellular immunity to varicella-zoster virus in patients with major depression. J. Infect. Dis. 178 (1998), 104–8.
74. F. S. Dhabhar, Acute stress enhances while chronic stress suppresses skin immunity: the role of stress hormones and leukocyte trafficking. Ann. N. Y. Acad. Sci. 917 (2000), 876–93.
75. I. Hickie, C. Hickie, A. Lloyd, D. Silove, D. Wakefield, Impaired in vivo immune responses in patients with melancholia. Br. J. Psychiatry 162 (1993), 651–7.
76. M. Shinkawa, K. Nakayama, H. Hirai, M. Monma, H. Sasaki, Depression and immunoreactivity in disabled older patients. J. Am. Geriatr. Soc. 50 (2002), 198–9.
77. R. Glaser, J. K. Kiecolt-Glaser, R. H. Bonneau, et al., Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosom. Med. 54 (1992), 22–9.
78. J. K. Kiecolt-Glaser, R. Glaser, S. Gravenstein, W. B. Malarkey, Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 3043–7.
79. K. Vedhara, N. K. Cox, G. K. Wilcock, et al., Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet 353 (1999), 627–31.
80. K. Vedhara, M. P. McDermott, T. G. Evans, et al., Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications. J. Psychosom. Res. 53 (2002), 1153–61.
81. N. Rohleder, N. C. Schommer, D. H. Hellhammer, R. Engel, C. Kirschbaum, Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosom. Med. 63 (2001), 966–72.
82. M. Irwin, A. Mascovich, J. C. Gillin, et al., Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom. Med. 56 (1994), 493–8.
83. M. Irwin, J. McClintick, C. Costlow, et al., Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 10 (1996), 643–53.
84. M. Irwin, T. L. Smith, J. C. Gillin, Electroencephalographic sleep and natural killer activity in depressed patients and control subjects. Psychosom. Med. 54 (1992), 107–26.
85. H. Cover, M. Irwin, Immunity and depression: insomnia, retardation, and reduction of natural killer cell activity. J. Behav. Med. 17 (1994), 217–23.
86. N. Castanon, B. E. Leonard, P. J. Neveu, R. Yirmiya, Effects of antidepressants on cytokine production and actions. Brain Behav. Immun. 16 (2002), 569–74.
87. E. Goujon, P. Parnet, S. Laye, et al., Stress downregulates lipopolysaccharide-induced expression of proinflammatory cytokines in the spleen, pituitary, and brain of mice. Brain Behav. Immun. 9 (1995), 292–303.
88. N. Barden, Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J. Psychiatry Neurosci. 24 (1999), 25–39.
89. R. Yirmiya, J. Weidenfeld, Y. Pollak, et al., Cytokines, ‘depression due to a general medical condition’, and antidepressant drugs. Adv. Exp. Med. Biol. 461 (1999), 283–316.
90. I. Yaron, L. Shirazi, R. Judovich, et al., Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 42 (1999), 2561–8.
91. F. Hindmarch, Expanding the horizons of depression: beyond the monoamine hypothesis. Hum. Psychopharm. 16 (2001), 203–18.
92. M. Kubera, G. Kenis, E. Bosmans, et al., Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol. 4 (2004), 185–92.
93. M. Irwin, U. Lacher, C. Caldwell, Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol. Med. 22 (1992), 1045–50.
94. S. J. Schleifer, S. E. Keller, J. A. Bartlett, Depression and immunity: clinical factors and therapeutic course. Psychiatry Res. 85 (1999), 63–9.
95. M. G. Frank, S. E. Hendricks, D. R. Johnson, J. L. Wieseler, W. J. Burke, Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology 39 (1999), 18–24.
96. Y. Kim, I. B. Suh, H. Kim, et al., The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 7 (2002), 1107–14.
97. G. Kenis, M. Maes, Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5 (2002), 401–12.
98. A. Sluzewska, Indicators of immune activation in depressed patients. Adv. Exp. Med. Biol. 461 (1999), 59–73.
99. M. Maes, S. Scharpe, H. Y. Meltzer, et al., Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 49 (1993), 11–27.
100. M. Maes, E. Bosmans, H. Y. Meltze, S. Scharpe, E. Suy, Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression. Am. J. Psychiatry 150 (1993), 1189–93.
101. M. Irwin, M. Daniels, S. C. Risch, E. Bloom, H. Weiner, Plasma cortisol and natural killer cell activity during bereavement. Biol. Psychiatry 24 (1988), 173–8.
102. C. Raison, A. H. Miller, When not enough is toomuch: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160 (2003), 1554–65.
103. M. L. Sopori, W. Kozak, Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83 (1998), 148–56.
104. J. A. Rosecrans, L. D. Karin, Effects of nicotine on the hypothalamic-pituitary-axis (HPA) and immune function: introduction to the Sixth Nicotine Round Table Satellite, American Society of Addiction Medicine Nicotine Dependence Meeting. Psychoneuroendocrinology 23 (1998), 95–102.
105. C. G. McAllister-Sistilli, A. R. Caggiula, S. Knopf, et al., The effects of nicotine on the immune system. Psychoneuroendocrinology 23 (1998), 175–87.
106. W. Jung, M. Irwin, Reduction of natural killer cytotoxic activity in major depression: interaction between depression and cigarette smoking. Psychosom. Med. 61 (1999), 263–70.
107. M. A. Mendall, P. Patel, M. Asante, et al., Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78 (1997), 273–7.
108. R. W. Linkins, G. W. Comstock, Depressed mood and development of cancer. Am. J. Epidemiol. 132 (1990), 962–72.
109. M. A. Schuckit, J. E. Tipp, M. Bergman, et al., Comparison of induced and independent major depressive disorders in 2945 alcoholics. Am. J. Psychiatry 54 (1997), 948–57.
110. M. Irwin, C. Caldwell, T. L. Smith, et al., Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity: role of severity of depressive symptomsand alcohol consumption. Arch. Gen. Psychiatry 47 (1990), 713–19.
111. M. Irwin, M. Schuckit, T. L. Smith, Clinical importance of age at onset in Type 1 and Type 2 primary alcoholics. Arch. Gen. Psychiatry 47 (1990), 320–24.
112. M. Irwin, G. Rinetti, L. Redwine, S. Motivala, C. Ehlers, Pro-inflammatory cytokines and disordered sleep in alcohol dependence. Psychosom. Med. 65 (2003), A-4.
113. M. Hall, A. Baum, D. J. Buysse, et al., Sleep as a mediator of the stress-immune relationship. Psychosom. Med. 60 (1998), 48–51.
114. M. Irwin, C. Clark, B. Kennedy, J. Christian Gillin, M. Ziegler, Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav. Immun. 17 (2003), 365–72.
115. J. Savard, L. Laroche, S. Simard, H. Ivers, C. M. Morin, Chronic insomnia and immune functioning. Psychosom. Med. 65 (2003), 211–21.
116. M. Irwin, J. C. Gillin, J. Dang, et al., Sleep deprivation as a probe of homeostatic sleep regulation in primary alcoholics. Biol. Psychiatry 51 (2002), 632–41.
117. M. Irwin, C. Miller, J. C. Gillin, A. Demodena, C. L. Ehlers, Polysomnographic and spectral sleep EEG in primary alcoholics: an interaction between alcohol dependence and African-American ethnicity. Alcohol Clin. Exp. Res. 24 (2000), 1376–84.
118. L. Redwine, J. Dang, M. Hall, M. Irwin, Disordered sleep, nocturnal cytokines, andimmunity in alcoholics. Psychosom. Med. 65 (2003), 75–85.
119. P. H. Black, L. D. Garbutt, Stress, inflammation and cardiovascular disease. J. Psychosom. Res. 52 (2002), 1–23.
120. L. Redwine, S. Snow, P. Mills, M. Irwin, Acute psychological stress: effects on chemotaxis and cellular adhesion molecule expression. Psychosom. Med. 65 (2003), 598–603.
121. M. U. Goebel, P. J. Mills, M. R. Irwin, M. G. Ziegler, Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom. Med. 62 (2000), 591–8.
122. J. F. Sheridan, C. Dobbs, D. Brown, B. Zwilling, Psychoneuroimmunology: stress effects on pathogenesis and immunity during infection. Clin. Microbiol. Rev. 7 (1994), 200–12.
123. S. Cohen, G. Miller, Stress, immunity and susceptibility to upper respiratory infection. In Psychoneuroimmunology, 3rd edn, ed. R. Ader, D. Felten, N. Cohen (San Diego, CA: Academic Press, 2000), pp. 499–509.
124. S. W. Cole, B. D. Naliboff, M. E. Kemeny, et al., Impaired response to HAART in HIVinfected individuals with high autonomic nervous system activity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 12 695–700.
125. S. W. Cole, M. E. Kemeny, S. E. Taylor, Social identity and physical health: accelerated HIV progression in rejection-sensitive gay men. J. Pers. Soc. Psychol. 72 (1997), 320–35.
126. S. W. Cole, Y. D. Korin, J. L. Fahey, J. A. Zack, Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J. Immunol. 161 (1998), 610–16.
127. E. M. Sternberg, G. P. Chrousos, R. L. Wilder, P. W. Gold, The stress response and the regulation of inflammatory disease. Ann. Intern. Med. 117 (1992), 854–66.
128. L. J. Crofford, K. T. Kalogeras, G. Mastorakos, et al., Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol Metab. 82 (1997), 1279–83.
129. C. Dickens, L. McGowan, D. Clark-Carter, F. Creed, Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med. 64 (2002), 52–60.
130. A. J. Zautra, B. W. Smith, Depression and reactivity tostress in olderwomenwith rheumatoid arthritis and osteoarthritis. Psychosom. Med. 63 (2001), 687–96.
131. J. M. Smyth, A. A. Stone, A. Hurewitz, A. Kaell, Effects of writing about stressful experiences on symptomreduction in patients with asthma or rheumatoid arthritis: a randomized trial. J. Am. Med. Assoc. 281 (1999), 1304–9.